Genotyping Market Size

Global Genotyping Market Overview

Genotyping Market Size was valued at USD 6.5 billion in 2022. The genotyping market industry is projected to grow from USD 7.94 Billion in 2023 to USD 39.5 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 22.2% during the forecast period (2023 - 2032). Due to the anticipated rise in genetic illness, technological advancements, a sharp increase in demand for tailored treatment, and rising research and development activities in the healthcare sector are the key market drivers enhancing the market growth. Moreover, the lower prices of genotyping services also aid the growing market.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

In February 2024, Benchmark Holdings' genetics division, a corporation specializing in aquaculture biotechnology, has broadened its range of products and services by introducing cost-effective genotyping instruments and services. Benchmark Genetics has announced a new offering that allows for tissue sample-to-data genotyping at a cost of €14.50 (£12.41) per sample. This step greatly enhances the availability of advanced genomic tools in the worldwide business, positioning Benchmark as a full provider of genetic support services. This expansion is founded on the extensive expertise of Benchmark Genetics and the Akvaforsk Genetics Centre. It is the result of years of designing and providing technical assistance for selection programs in over 20 aquaculture species globally. The company currently provides a comprehensive range of genetic enhancement services, including complex multi-trait programs and cost-effective, focused programs that can easily integrate into existing commercial agricultural operations. Benchmark's revised offering encompasses high-density arrays and genotyping services for a diverse variety of farmed aquaculture species, as well as medium-density solutions for other species. The solution takes advantage of Benchmark's extensive genotyping capabilities in its salmon and shrimp breeding programs. Services include high-density array genotyping starting at €14.5 for multiple species.

In September 2023, Bio-Rad Laboratories, Inc., a prominent company in the field of life science research and clinical diagnostics, introduced the PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers. These devices are specifically designed to facilitate PCR applications in various areas such as basic and translational research, process development, and quality control. The PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers are the most recent models included in Bio-Rad's collection of traditional PCR thermal cyclers. The PTC Tempo Thermal Cyclers have been designed with an updated and user-friendly interface, as well as versatile connectivity tools to simplify protocol management. These features include the ability to monitor and control the cyclers using the BR.io cloud platform. The PTC Tempo Thermal Cyclers are designed to consistently provide excellent thermal performance. These cyclers give scientists the ability to easily adjust and expand their experiments within the laboratory. The PTC Tempo 48/48 Thermal Cycler is equipped with two separate dual blocks and manual lids, enabling the concurrent execution of two independent protocols. The PTC Tempo 384 Thermal Cycler is designed for laboratories that handle a large number of samples. It is equipped with a motorized top, allowing for automation compatibility and interface with robotics.

Genotyping Market Trends

• Growing Prevalence of spine degeneration to boost the market growth

The  genotyping market is majorly driving the demand for genotypic-based diagnostic testing in healthcare facilities worldwide. Various attributes affect the genotyping market, such as the increased Prevalence of chronic diseases, cancer, and genetic disorders. Along with this, the rising adoption of bioinformatics solutions in pharmacogenomics and data analysis in the discovery of drug and development processes is also a stimulus for market growth. With the significant rise in the investments in research and development work solely focusing on research of precision medicine and development of the genomic drug. Other than the above factors, there is a positive outlook on the  market growth due to the ever-increasing demands for reagents for the augmenting volumes of tests related to genotyping.

Apart from this, the factors that are contributing to the  genotyping market revenue growth include the rising elderly population, as they are more susceptible to developing numerous medical conditions, the rise in awareness related to personalized medicines among the common people, continual technological development in the genotyping products and significant expansion of the healthcare expenditures.

Genotyping Market Segment Insights

Genotyping Technology Insights

Based on technology, the genotyping market segmentation includes Sequencing, Capillary Electrophoresis, Polymerase Chain Reaction (PCR), and others. In 2022, the PCR segment controlled the market and had the biggest revenue share. This large market share may be attributed to the expanding need for sophisticated diagnostic methods, the rise of CROs, forensic and research laboratories and the rising Prevalence of diseases, including genetic disorders and chronic illnesses.

Sequencing's increased specificity and superior capacity to detect low expression & differentially expressed genes compared to other approaches are further reasons for its prediction to grow profitably during the projection period. Without a reference genome, a comparative examination of samples can be carried out with the aid of genotyping by sequencing.

Genotyping Product Insights

Based on product, the genotyping market segmentation includes reagents and kits, instruments, and services. In 2022, the market for reagents and kits had the biggest share. Rising R&D expenditures, genotyping testing volumes, and genetic testing demand brings this on. Due to the increasing usage of software-based services by research laboratories and academic institutions, it is also projected that the software & services market will grow at a high rate. The effectiveness of sequencing techniques is increased by using bioinformatics, and errors made by conventional sequencing techniques are reduced. Applications for these services can be found in agrigenomics, human diseases, animals, and microorganisms. All of the factors above are expected to drive market growth throughout the projection period.

Figure 1 Genotyping Market, by Product, 2022 & 2030 (USD billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Genotyping Application Insights

The genotyping market data has been bifurcated by application into drug discovery and development, academic research, and research and development centers. During the projected period, drug discovery and development are anticipated to increase at the quickest rate of any technology. Based on the patient's genetic makeup, genotyping assists in identifying individuals who are suited for a certain medicine. The attrition rate in clinical trials can be decreased by identifying population subsets that are responsive or non-responsive to provide these patients with individualized treatment. Key players also contribute actively by offering drug discovery and development research remedies. For instance, TaqMan assays and QuantStudio tools are included in Thermo Fisher Scientific's RT PCR solution for pharmacogenomic testing. Together with a PharmacoScan Assay Kit, it also offers a PharmacoScan solution.

Genotyping End User Insights

Based on End Users, the genotyping industry has been segmented into hospitals, diagnostic centers, academic institutes, and research and development centers. Due to the rising usage of genotyping products for research and the rising need for diagnosing genetic illnesses & cancer, the diagnostic center market is anticipated to grow at the fastest CAGR rate during the forecast period. The market is anticipated to be driven by the rising frequency of cancer and the rising demand for diagnostic tests such as cancer genotyping assays.

Genotyping Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. North America Genotyping market accounted for USD 3.0 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period, attributable to the rising use of technologically improved products, the existence of large pharmaceutical & biopharmaceutical businesses, proactive government actions, and developments in healthcare infrastructure. The presence of significant players in this Region is another key reason responsible for the high market share.

Further, the major countries studied in the market report are The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 GENOTYPING MARKET SHARE BY REGION 2022 (%)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe genotyping market accounts for the second-largest market share due to several variables, including technical developments and the expanding pharma and biopharma business in the area, which can be blamed for the vast latent growth. Further, the Germany genotyping market held the largest market share, and the UK genotyping market was the fastest-growing market in the European Region.

The Asia-Pacific Genotyping Market is expected to grow at the fastest CAGR from 2022 to 2030. This is due to the increased number of clinical trials. Moreover, the China genotyping market held the largest market share, and the India genotyping market was the fastest-growing in Asia-Pacific.

Genotyping Key Market Players & Competitive Insights

Leading market players are investing a lot of money in R&D to expand their product portfolios, which will spur further growth for Genotyping industry. With significant industry changes like new product releases, contractual agreements, mergers and acquisitions, increased investments, market developments and collaboration with other organizations, market participants are also undertaking various strategic activities to expand their presence. Genotyping industry competitors must provide affordable products to grow and remain in a market that is becoming increasingly competitive.

Manufacturing locally to cut operational costs is one of the main business tactics used by genotyping manufacturers to serve customers and increase the market sector. The genotyping market major player such as QIAGEN, Affymetrix, Illumina, Thermo Fisher Scientific, and others are working on expanding the market demand by investing in research and development activities.

More than 140 nations are served by the American biotechnology corporation Illumina, Inc., headquartered in San Diego, California. Illumina, founded on April 1, 1998, creates, produces, and sells integrated systems for studying genetic variation and biological function. The business offers a selection of goods and services to cater to the markets for sequencing, genotyping and gene expression, and proteomics. Illumina and Roche worked together in January 2020 to increase patient access to oncology genomic testing.

Thermo Fisher Scientific Inc. Thermo Fisher, headquartered in Waltham, Massachusetts, is an American provider of scientific equipment, reagents, consumables, and software services. It was created in 2006 by the union of Thermo Electron and Fisher Scientific. Several reagent, consumable, instrument, and service suppliers have been purchased by Thermo Fisher Scientific, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021). Thermo Fisher Scientific increased its production capacity in August 2021. To diagnose the Delta and Lambda strains of SARS-CoV-2, the business updated its Applied Biosystems TaqMan SARS-CoV-2 mutation panel. The panel allows labs to monitor known mutations by letting them choose from a list of more than 50 assays made to screen for various variants.

Key Companies in the genotyping market include

• QIAGEN


• Affymetrix


• Illumina


• Thermo Fisher Scientific


• General Electric Company


• Agilent Technologies


• Fluidigm Corporation


• Sequenom


• Hoffmann-La Roche Ltd


• Beckman Coulter, among others

Genotyping Developments

February 2021 SNPsig portfolio of PCR genotyping assays is launched by Novacyt. It can be used in the diagnosis of the variants of SARS-CoV-2.

August 2021 Thermo Fisher Scientific has expanded the production capacity of their organization. The company has upgraded its Applied Biosystems TaqMan SARS-CoV-2 mutation panel to diagnose the Delta and Lambda strains. For tracking the known mutations, the panels provide the feature of selecting more than 50 assays designed for analyzing different variants in the laboratories.

Genotyping Market Segmentation

Genotyping Technology Outlook

• Sequencing


• Capillary Electrophoresis


• PCR


• Others

Genotyping Product Outlook

• Reagents and Kits


• Instruments


• Services

Genotyping Application Outlook

• Diagnostics


• Drug Discovery and Development


• Academic Research


• Research and Development Centers

Genotyping End User Outlook

• Hospitals


• Diagnostic Centers


• Academic Institutes


• Research and Development Centers

Genotyping Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America